HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target

Benzinga · 06/03 11:15
HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $80 price target.